As shown in Figures 2A, B, the LMDP peptide consists of a three-part combination including a PD-L1 antagonist short D-peptide (DPPA-1), a MMP2-reactive peptide (PLGVRG) and LyP-1 (CGNKRTRGC) sequence identical to tumor homing ligand, which endow Au@Pt-LMDP with high tumor inhibition and the alleviation of metastasis, especially the lung metastasis, via enhancing population of the CD8+ T cells and downregulating the Treg activity when combination with PTT. Here, CD8A is linked to neoplasm.